NovoCure (NVCR) reported $154.99 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 11.9%. EPS of -$0.31 for the same period compares to -$0.36 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $147.57 million, representing a surprise of +5.03%. The company delivered an EPS surprise of +34.04%, with the consensus EPS estimate being -$0.47.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how NovoCure performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net revenues- Greater China: $4.62 million versus $3.79 million estimated by two analysts on average.
- Net revenues- International markets - Total: $57.22 million versus $53.77 million estimated by two analysts on average.
- Net revenues- Japan: $8.71 million versus $8.70 million estimated by two analysts on average.
- Net revenues- United States: $93.15 million versus the two-analyst average estimate of $90.92 million.
View all Key Company Metrics for NovoCure here>>>
Shares of NovoCure have returned -3.6% over the past month versus the Zacks S&P 500 composite's -5.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
NovoCure Limited (NVCR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
